Have a personal or library account? Click to login
D-Amphetamine Toxicity in Freshly Isolated Rat Hepatocytes: A Possible Role of CYP3A Cover

D-Amphetamine Toxicity in Freshly Isolated Rat Hepatocytes: A Possible Role of CYP3A

Open Access
|Jul 2009

References

  1. Caldwell J. The metabolism of amphetamines and related stimulants in animals and man. In: Caldwell J, editor. Amphetamines and related stimulants: Chemical biological and sociological aspects. Boca Raton: CRC Press Inc.; 1980. p. 29-46.10.1201/9780429279843-3
  2. Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 1999;29:719-32.10.1080/00498259923834410456690
  3. Law MY, Slawson MH, Moody DE. Selective involvement of cytochrome P450 2D subfamily in in vivo 4-hydroxylation of amphetamine in rat. Drug Metab Dispos 2000;28:348-53.
  4. Carvalho F, Remião F, Amado F, Domingues P, Correia AJ, Bastos ML. D-Amphetamine interaction with glutathione in freshly isolated rat hepatocytes. Chem Res Toxicol 1996;9:1031-6.10.1021/tx95017508870992
  5. Yanada H, Oguri K, Yoshimura H. Effects of several factors on urinary excretion of methamphetamine and its metabolites in rats. Xenobiotica 1986;16:137-41.10.3109/004982586090435163962334
  6. Timbrell J. 2000. Factors affecting metabolism and disposition — Enzyme inhibition. In: Principles of Biochemical Toxicology. 3rd ed. New York (NY): Taylor and Francis; 2000. p. 164-5.
  7. Graham RJ, Benet LZ. Antiprogestin-mediated inactivation of cytochrome P 450 CYP 3A4. Int J Exp Clin Pharmacol 1998;56:150-7.
  8. Council of Europe. European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes. CETS No. 123, 1991 [displayed 30 May 2007] Available at http://conventions.coe.int/treaty/Commun/QueVoulezVous.asp?NT=123ECL=ENG
  9. Vitcheva V, Mitcheva M. Effect of nifedipine on behavioral and biochemical parameters in rats after multiple morphine administration. Methods Find Exp Clin Pharmacol 2004;26:631-4.10.1358/mf.2004.26.8.86372915605124
  10. Fau D, Berson A, Eugene D, Formently B, Fisch C, Pessayre D. Mechanism for the hepatotoxicity of the antiandrogen Nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug lead to oxidative stress in isolated hepatocytes. J Pharm Exp Ther 1992;263:69-77.
  11. Mitcheva M, Kondeva M, Vitcheva V, Nedialkov P, Kitanov G. Effect of benzophenones from Hypericum annulatum on carbon tetrachloride-induced toxicity in freshly isolated rat hepatocytes. Redox Rep 2006;11:3-8.10.1179/135100006X10096816571270
  12. Ohyama K, Nakajiama M, Suzuki M, Shimada N, Yamazaki H, Yoki T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P 450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000;49:244-53.10.1046/j.1365-2125.2000.00134.x201491210718780
  13. Bergmeyer HU, editor. Methods of enzymatic analysis. Vol 1. New York (NY) / London: Verlag Chemie — Academic Press; 1974.
  14. Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Atten Disord 2007;11:8-16.10.1177/108705470629560517606768
  15. Carvalho F, Remião F, Soares ME, Catarino R, Queiroz G, Bastos ML. D-Amphetamine-induced hepatotoxicity: possible contribution of catecholamines and hyperthermia to the effects studied in isolated hepatocytes. Arch Toxicol 1997;71:429-36.10.1007/s0020400504079209688
  16. Jones AJ, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999;13:129-33.10.1046/j.1365-2036.1999.00454.x10102941
  17. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit 2004;26:127-31.10.1097/00007691-200404000-0000715228152
  18. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002;36:1598-613.10.1345/aph.1A44712243611
  19. Shulman A, Jagoda J, Laycock G, Kelly H. Calcium channel blocking drugs in the management of drug dependence, withdrawal and craving. A clinical pilot study with nifedipine and verapamil. Aust Fam Physician 1998;27(Suppl 1):S19-24.
  20. Kastelova A, Koleva M, Staneva-Stoytcheva D. Changes in rat liver monooxygenase activities after administration of atenolol, nifedipine and diltiazem alone and in combination. Methods Find Exp Clin Pharmacol 2000;22:627-31.10.1358/mf.2000.22.8.80227411256234
  21. Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, Vilarem MJ. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP 3A, CYP 2B and CYP 2C in human hepatocytes. Drug Metab Dispos 2001;29:1325-31.
  22. Diehl KH, Hull R, Morton D, Pfizer R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C. A good practice guide to the administration of substances and removal of blood, including routs and volumes. J Appl Toxicol 2001;21:15-23.10.1002/jat.72711180276
  23. Coleman MD. Human Drug Metabolism. West Sussex: John Wiley and Sons; 2006.
  24. Ha HR, Bigler L, Binder M, Korlik P, Stieger B, Heese M, Altorfer HR, Follath F. Metabolism of amiodarone (part I): identification of a new hydroxylated metabolite of amiodarone. Drug Metab Dispos 2001;29:152-8.
DOI: https://doi.org/10.2478/10004-1254-60-2009-1912 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 139 - 145
Published on: Jul 6, 2009
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2009 Vessela Vitcheva, Magdalena Kondeva-Burdina, Mitka Mitcheva, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons License.

Volume 60 (2009): Issue 2 (June 2009)